The Company
Background and Location
Illinois Synth was formed directly as a result of the collaboration of members from the 2012 University of Illinois iGEM Team. The company corporate headquarters and principal product development facility will be located at the University of Illinois Urbana-Champaign’s Institute for Genomic Biology. Upon expansion and generation of a consistent revenue stream, Illinois Synth will look to occupy the Enterprise Works Tech Incubator located at 60 Hazelwood Drive, Champaign IL.
Facilities
Illinois Synth’s manufacturing and laboratory facilities and equipment are all serviced regularly to maintain the highest performance standards consistent with aseptic technique. Additional capital equipment is projected subsequent to product release to utilize capacity and meet sales demand.
Legal Form of Business
The company will be incorporated as a C-Corporation in the state of Delaware.
Employees
The management team of six executives will look to conduct research and development independent of other employees for the first three quarters of company growth. Future expansion in the fourth quarter and beyond will require several production and sales personnel.
Executive Summary
The Company
Illinois Synth was formed in June 2012 to develop, market, and license products intended to further the progress of synthetic biology. Our founding team is comprised of six University of Illinois undergraduate students from a variety of backgrounds including bioengineering, biochemistry, molecular biology, agricultural engineering and chemical engineering. Brought together initially by the desire to work with synthetic biology in the context of the International Genetically Engineered Machines (iGEM) competition, we are now in the process of commercializing our research.
The Products
The two product lines being developed by Illinois Synth are as follows:
Gene Expression Modulator (GEM) Toolkit – a PUF protein domain-based customizable ssRNA-specific toolkit to modulate and regulate gene expression.
- In Vivo Optimized Piceatannol Cascade (IOPiC) – an RNA-scaffold based enzymatic conveyer belt designed to produce piceatannol from L-tyrosine.
The Market
Ever since the discovery of restriction enzymes in 1978, a new era of synthetic biology was ushered in, an era in which scientific discovery would meet engineering, and promised the ability to eventually control and modulate gene expression. Illinois Synth has a deep confidence not only in the growth of synthetic biology as an industry, but in the growing demand for technologies that will allow the modulation of gene expression in RNA. Such tools currently take the form of RNA recognition motifs, K Homology proteins, and CCCH Zinc Finger proteins that in many cases do not exhibit sequence specific binding, or are unable to be programmed to recognize specific, desired ssRNA sequences. With regard to the use of an in vivo enzymatic cascade to produce piceatannol, our analysis has shown that such a method would be faster, more efficient, and lower cost than chemical synthesis of the compound, which is the only current mode of production.
Competitive Analysis
Our competitive analysis was broken into two components:
- Analysis of alternative RNA-binding proteins
- Analysis of alternative ways to produce piceatannol
Analysis of alternative ways to bind to RNA yielded protein domains that are not as site specific as the PUF domain (8 nucleotide sequence specificity), and/or are uncustomizable whereas PUF can be programmed to recognize a desired ssRNA sequence while being tethered to a functional domain such as an endonuclease.
Chemical synthesis is the only current mode of production of piceatannol, and has proven to be expensive due to the inefficiency of the chemical process. Tocris Bioscience, in particular, has a base rate of $19/mg of piceatannol. Additionally, instead of competing directly with large pharmaceutical companies to produce piceatannol at a low cost, we intend to license our technology to companies interested in using our RNA scaffold.
Value Proposition
Our GEM Toolkit will provide an extremely novel, and efficient way to regulate and modulate gene expression in ssRNA. We expect such a toolkit to provide a high degree of utility to researchers interested in varying gene expression levels. Additionally, we believe IOPiC will provide a low cost, biological alternative to achieve the production of piceatannol without involving expensive chemical processes.
Marketing and Sales Plan
Illinois Synth will adopt a two-step marketing plan for its GEM Toolkit and IOPiC technologies. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price products. The specifics of the marketing strategy, including online marketing are detailed throughout the plan.
Management and Organization
Illinois Synth’s management board brings with it the ability to raise venture capital, make necessary contacts with representatives from academia and industry, and develop our products methodically through cutting-edge research and development. The board members come from a variety of scientific and engineering backgrounds, and also have the business development experience to set up the necessary infrastructure for Illinois Synth. In addition to the management board, Illinois Synth is advised by an advisory board that represents an exceptional set of professors, graduate students, and researchers from the University of Illinois. Resumes for management board members can be found in the Appendix.
Financial Summary
Illinois Synth will rely on equity financing, product sales, contract manufacturing, corporate partnerships, and interest income to fund its operations and capital expenditures. Negative cash flow due to research and development of the two product lines is expected to continue for a minimum of 15 months, through the first quarter of 2014. Due to the possible need for additional funds to expand product development, sales, and marketing capabilities, other sources of capital such as venture and angel investments will be explored. Future capital requirements will depend on a variety of factors, including:
- Progress in Research & Product development programs
- Relationships with corporate sponsors
- Relationships with academic or industrial collaborators
- Competing technological and market developments
- Patent filing, prosecuting, and filing costs
- Commercialization activities
- Industry Growth
Investor Summary
- Illinois Synth has a unique, significant and adaptable product line that is expected to generate rapid sales growth in an emerging industry.
- The members of Illinois Synth’s management team have backgrounds in engineering, molecular biology, and business development, making them uniquely suited to address the challenges associated with setting up a synthetic biology enterprise.
- Experienced advisory board including faculty and researchers from the University of Illinois.
- Logistical and technical support from the Institute for Genomic Biology at the University of Illinois, one of the premier biotechnology research institutions in the United States.
"
